Cannabis
Cannabis compounds CBD and THC show targeted effects against ovarian cancer cells in lab study
由 AI 报道 AI 生成的图像 事实核查
Laboratory research led by scientists at Khon Kaen University indicates that cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), two key cannabis compounds, can slow the growth and spread of ovarian cancer cells in vitro, particularly when used together in a 1:1 ratio, while causing relatively limited damage to healthy cells. The early-stage findings, reported in Frontiers in Pharmacology, suggest a potential avenue for future ovarian cancer treatments but are far from clinical use.
A study from the Texas Biomedical Research Institute indicates that micro-doses of THC, the active compound in cannabis, can mitigate long-term side effects of HIV treatment without causing intoxication. In rhesus macaques, low-dose THC reduced inflammation, boosted serotonin levels, and lowered harmful cholesterol and bile acids while maintaining viral suppression. The findings suggest potential for managing chronic complications in people living with HIV.
由 AI 报道
In the latest assessment following prior reviews like the 2025 Annals analysis showing limited THC benefits, a Cochrane review finds cannabis-based medicines offer no clinically meaningful relief for chronic neuropathic pain versus placebo. Analyzing 21 randomized trials with over 2,100 adults, it reports no high-quality evidence of effectiveness, with only minor, insignificant improvements from THC-CBD combinations.
A new study presented at the American College of Surgeons Clinical Congress found that nearly 42% of drivers killed in crashes in Ohio had active THC in their blood, with levels far exceeding legal limits. The prevalence remained unchanged even after recreational cannabis legalization in 2023. Researchers urge stronger public messaging on the risks of driving after marijuana use.
由 AI 报道
A cannabis-derived mouth spray has shown significant effectiveness in reducing chronic lower back pain, according to a new clinical study. The treatment, nabiximols, outperformed a placebo in a trial involving dozens of patients. Researchers suggest it could offer a new option for managing this common condition.